---
title: "Grand Pharmaceutical Group kündigt Übernahme von Hebei Yuanda Jiufu Biotechnology und Baoding Jiahe Fine Chemical an"
description: "Grand Pharmaceutical Group Ltd. has announced the full acquisition of Hebei Yuanda Jiufu Biotechnology Co., Ltd. and Baoding Jiahe Fine Chemical Co., Ltd. for a purchase price of 316 million RMB. This"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/274626815.md"
published_at: "2026-02-03T09:06:50.000Z"
---

# Grand Pharmaceutical Group kündigt Übernahme von Hebei Yuanda Jiufu Biotechnology und Baoding Jiahe Fine Chemical an

> Grand Pharmaceutical Group Ltd. has announced the full acquisition of Hebei Yuanda Jiufu Biotechnology Co., Ltd. and Baoding Jiahe Fine Chemical Co., Ltd. for a purchase price of 316 million RMB. This price was determined after negotiations and based on an independent assessment valuing the target companies at approximately 324 million RMB as of September 30, 2025. The announcement includes details on the valuation methodology, particularly the use of the Enterprise-Value-to-Sales multiple to reflect recent business performance and capital structure.

Grand Pharmaceutical Group Ltd. hat den vollständigen Erwerb der gesamten Beteiligungen an Hebei Yuanda Jiufu Biotechnology Co., Ltd. und Baoding Jiahe Fine Chemical Co., Ltd. bekannt gegeben. Der Kaufpreis beläuft sich auf 316 Millionen RMB und wurde nach Verhandlungen sowie auf Basis eines unabhängigen Gutachtens festgelegt, das den Wert der Zielunternehmen auf rund 324 Millionen RMB zum Stichtag 30. September 2025 beziffert. In der aktuellen Mitteilung wurden zusätzliche Informationen zur Bewertungsmethodik bereitgestellt, insbesondere zum Einsatz des Enterprise-Value-to-Sales-Multiples, um die jüngste Geschäftsentwicklung und Kapitalstruktur zu berücksichtigen. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Grand Pharmaceutical Group Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260203-12011545), on February 03, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [159992.CN - Yinhua CSI Innovative Drugs Industry ETF](https://longbridge.com/en/quote/159992.CN.md)
- [00512.HK - GRANDPHARMA](https://longbridge.com/en/quote/00512.HK.md)
- [588130.CN - ChinaAMC SSE STAR Biology and Medicine ETF](https://longbridge.com/en/quote/588130.CN.md)
- [520690.CN - Bosera Hang Seng SCHK Innovative Drug Select ETF](https://longbridge.com/en/quote/520690.CN.md)
- [159849.CN - China Merchants CSI Biotechnology Theme ETF](https://longbridge.com/en/quote/159849.CN.md)
- [HYYLL.HK - 捍宇医疗](https://longbridge.com/en/quote/HYYLL.HK.md)
- [520880.CN - Hwabao WP Hang Seng SCHK Innovative Drug Select ETF](https://longbridge.com/en/quote/520880.CN.md)
- [159316.CN - E Fund Hang Seng SCHK Innovative Drug ETF](https://longbridge.com/en/quote/159316.CN.md)
- [159506.CN - Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF](https://longbridge.com/en/quote/159506.CN.md)
- [562050.CN - Hwabao WP CSI Pharmaceuticals ETF](https://longbridge.com/en/quote/562050.CN.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Shanghai Fosun Pharmaceutical Units Trial Nod for Lung Cancer Drug in China | Shanghai Fosun Pharmaceutical Units Trial Nod for Lung Cancer Drug in China | [Link](https://longbridge.com/en/news/276886600.md) |
| Japan MHLW Approves High-Dose BESREMi Regimen for PharmaEssentia | PharmaEssentia Corporation announced that Japan's Ministry of Health, Labour and Welfare has approved a high-dose regime | [Link](https://longbridge.com/en/news/277488444.md) |
| China Medical System Gets China Acceptance for Atopic Dermatitis Drug | China Medical System Gets China Acceptance for Atopic Dermatitis Drug | [Link](https://longbridge.com/en/news/276718382.md) |
| Shanghai Pharmaceuticals Obtains Singapore Marketing Approval for Anticoagulant Drug | Shanghai Pharmaceuticals Obtains Singapore Marketing Approval for Anticoagulant Drug | [Link](https://longbridge.com/en/news/276822785.md) |
| Henlius Biotech Doses First Patient in Phase 2/3 Breast Cancer Drug Study; Shares Slip 3% | Henlius Biotech Doses First Patient in Phase 2/3 Breast Cancer Drug Study; Shares Slip 3% | [Link](https://longbridge.com/en/news/277421361.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.